CTOs on the Move

St Charles Parish Hospital

www.stch.net

 
St Charles Parish Hospital is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Luling, LA. To find more information about St Charles Parish Hospital, please visit www.stch.net
  • Number of Employees: 1K-5K
  • Annual Revenue: $10-50 Million
  • www.stch.net
  • 1057 Paul Maillard Rd
    Luling, LA USA 70070-4349
  • Phone: 985.785.3662

Executives

Name Title Contact Details

Similar Companies

Four Corners Health Care Ctr

Four Corners Health Care Ctr is a Durango, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Success Healthcare

Success Healthcare, LLC. is an organization that manages and owns community-based acute care hospitals supported by a management team dedicated to operations and financial excellence. Our goal is to deliver consistent quality cost-efficient patient care, and programs that best serve as well as respect each individual hospital`s distinctive mission and values, its physicians, employees, and community-at-large. To do so, we provide expertise in operations, clinical, and financial resources to each of our hospitals. To deliver quality and compassionate healthcare to our patients through our employees and the physicians who practice in the communities we serve.

lifeIMAGE

lifeIMAGE is an interoperable medical image sharing network that helps healthcare providers access their patients` imaging records, regardless of where exams are performed or stored. It has been adopted by more than 120 multi-site health systems across the country to improve care coordination for patient consultations, referrals and transfers. This enables providers to improve the quality and timeliness of care, expand referral business, and eliminate wasteful spending.

intellyst Medical Communications

intellyst Medical Communications is a Aurora, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OncoCell MDx

OncoCellMDx is a privately held company dedicated to the development and commercialization of novel diagnostic tests utilizing proprietary technologies created at Harvard Medical School. In particular, we have developed a noninvasive blood-based immunogenomic assays that will aid the physician to better understand the underlying pathology. The first product is for assessing the severity of prostate cancer. Other oncology indications as well as non-oncology indications are part of our pipeline. The assay is based on examining specific transcription levels between phagocytic and non-phagocytic cells. This proprietary technology and algorithm has allowed us to not only detect disease but to also, and more importantly, guide the physician as to the grade and aggressiveness of the disease. Our mission is to provide clinicians with quantifiable results that allows professionals to make timely and much more directed medical decisions.